An accurate determination of human epidermal growth factor receptor 2 (Her2) status in women with breast cancer is mandatory to identify patients who will benefit from trastuzumab-based therapy.
Pennacchia, I., Vecchio, F. M., Carbone, A., Arena, V., HER2 immunohistochemical assessment with A0485 polyclonal antibody: is it time to refine the scoring criteria for the "2+" category?, <<APPLIED IMMUNOHISTOCHEMISTRY AND MOLECULAR MORPHOLOGY>>, 2015; 23 (1): 31-35. [doi:10.1097/PAI.0000000000000047] [http://hdl.handle.net/10807/70983]
HER2 immunohistochemical assessment with A0485 polyclonal antibody: is it time to refine the scoring criteria for the "2+" category?
Pennacchia, Ilaria;Vecchio, Fabio Maria;Carbone, Arnaldo;Arena, Vincenzo
2015
Abstract
An accurate determination of human epidermal growth factor receptor 2 (Her2) status in women with breast cancer is mandatory to identify patients who will benefit from trastuzumab-based therapy.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
